Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Sarcoma 1Lymphoid 1

Conditions

Depression 6Neoplasms 5Anxiety Disorders 5Melanoma 2Depressive Disorder, Major 2Pain 1Osteosarcoma 1Opioid-Related Disorders 1Neoplasm Metastasis 1Lymphoma 1Hospice 1Hematopoietic and Lymphatic System Neoplasm 1Endocrine Gland Neoplasms 1Depressive Disorder 1Caregiver Distress 1Carcinoma, Non-Small-Cell Lung 1Agnosia 1

Interventions

Ipilimumab 106Nivolumab 101pembrolizumab 90aldesleukin 72Cyclophosphamide 46Interleukin-2 45Temozolomide 36Dacarbazine 32trametinib 31dabrafenib 30fludarabine phosphate 29incomplete Freund's adjuvant 27Bevacizumab 26sargramostim 25Vemurafenib 25fludarabine 22binimetinib 21Radiosurgery 21Paclitaxel 20encorafenib 19Carboplatin 19CTLA-4 Antigen 18cobimetinib 16atezolizumab 15Radiotherapy 14Biopsy 14Sorafenib 13MART-1 Antigen 12talimogene laherparepvec 11montanide ISA 51 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Melanoma × Psilocybin × Clear all
NCT06416085 2026-03-05

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer

University Health Network, Toronto

Phase 2 Active not recruiting
15 enrolled
DermatologicLymphoidSarcoma

Endocrine Gland Neoplasms, Lymphoma, Melanoma, Osteosarcoma

NCT00979693 2023-12-26

Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma

Multidisciplinary Association for Psychedelic Studies

Phase 2 Withdrawn
Dermatologic

Anxiety Disorders, Depression, Melanoma, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡